Skip to main content

Table 2 Pharmacokinetic studies of epinephrine autoinjectors. Comparison of injection in the middle part of the antero-lateral (m a-l) or distal-ventral (d-v) area of the thigh

From: The pharmacokinetics of epinephrine/adrenaline autoinjectors

Subject\Study

Simons et al.

Edwards et al. 2013 [10]

Duvauchelle et al. 2018 [11]

Worms et al. [12]

Turner et al. [13]

1998 [8]

2001 [9]

  

Low STMD

Middle STMD

High STMD

 

Brand

Epipen®

Epipen®

Epipen®

Auvi-Q®

Anapen®

Anapen®

Anapen®

Epipen®

Epipen®

Epipen®

Emerade®

Emerade®

Needle length, mmj

10.5

15

15

15

10.5

10.5

10.5

13–18 (20)

13–18 (20)

13–18 (20)

23

23

Number of pat.

8

13

135

67

18

12

18

12

12

11

12

12

Gender

Children

Male, adults

Male, adults

Male, adults

Male, adults

Female, adults

Male, adults

M = 6; F = 6

M = 6; F = 6

M = 5; F = 6

Adolescent

M = 7; F = 5

Adolescent

M = 7; F = 5

Weight kg

?

15–40

85 ± 5; 62–114

77.0 ± 11.5

77.0 ± 11.5

75 ± 10.5

78 ± 7.9

75 ± 10.5

M/F 103.5/63.6

M/F 107.7/83.3

M/F 122.4/85.0

61

41.8–76.4

61

41.8-76.4

BMI kg/m2

36.6 ± 4.6; 29–64

25.4 ± 2.7

25.4 ± 2.7

23.3 ± 1.9; 18–26

29.7 ± 1.9; 26–34

23.3 ± 1.9; 18–26

M/F 32.4/21.3

M/F 32.2/28.1

M/F 36./31.4

Age years

4–12

18–35

33.2 ± 6.3

33.2 ± 6.3

31.5 ± 9.2

33.3 ± 9.1

31.5 ± 9.2

M/F 36.2/46.0

M/F 34.5/38.8

M/F 32.8/39.0

15.4

15.4

Site

?

Thigh, m a-l

Thigh, m a-l

Thigh, m a-l

Thigh, m a-l

Thigh, d-v

Thigh, m a-l

Thigh, m a-l

Thigh, m a-l

Thigh, m a-l

Thigh m a-l

Thigh m a-l

Rote

i.m.a

i.m.a

i.m.a

i.m.a

i.m.

i.m.a i

i.m.

i.m.a

i.m.a

i.m.a

i.m.

i.m.

Dose mg

0.3

0.3

0.3

0.3

0.3

0.3

0.3

0.3

0.3

0.3

0.3

0.5

Plasma level analyzes hours

3

3

6

6

6

6

6

6

6

6

3

3

Tmax 1, minutes

8 ± 2c

5

10f

5–10g; 5i

5–10g; 5i

12 ± 7; 5d

14 ± 6; 15d

13 ± 7; 5d

9 (3–60)

10,5 (2–39)

30 (9–120)

Tmax 2, minutes

≈ 20e

≈ 40f

25–308)

25–30h

≈ 50d

≈ 30d

≈ 50d

Cmax1 pg/ml

2136 ± 351

12,222 ± 3829

520

486

377. ± 298

275d

440 ± 416

≈ 250d

353.9 ± 283

≈260d

M/F

400/640

M/F

480/520

M/F

420/630

Cmax2 pg/ml

1000f

≈ 6000f

≈ 300h

≈ 330h

≈ 250d

≈ 275d

≈290d

No of Cmax

1?

2

2

2

2

2?

2

2

2

2

2

2

AUC0-20 h*pg/mk

69.3 ± 54

55.9 ± 45

68.4 ± 50

   

AUC0-t h*pg/ml

466

536

M/F 273/288

M/F 281/209

M/F

263/311

AUCinf h*pg/ml

108,000 ± 18,000

583

724

459.2 ± 129

677.7 ± 161

473.1 ± 139

  1. aIntended localization of the bolus; cIn the s.c. group, 2/9 children and in the i.m. group, 6/8 children showed a Tmax at 5 min. [8]; d Estimated from Figure 3 in [11]; e Estimated from Figure 1 in [8]. f According to Figure 1 in [9]; g Approximately according to Table 3 in [10]; h According to Figure 2 in [10]; i s.c. in 10/12 women, i.m in 2/12 women as localized by ultrasound [10]. j The variation 5 mm for Epipen®, not known for Anapen® [11, 27]; k Worm [12]: AUC registered for 6, 15 and 30 min, but data not reported